These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 33433804)

  • 1. Price Is Right: Exploring Prescription Drug Coverage Barriers for Irritable Bowel Syndrome Using Threshold Pricing Analysis.
    Shah ED; Chang L; Lembo A; Staller K; Curley MA; Chey WD
    Dig Dis Sci; 2021 Dec; 66(12):4140-4148. PubMed ID: 33433804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value-based Pricing for Rifaximin Increases Access of Patients With Irritable Bowel Syndrome With Diarrhea to Therapy.
    Shah ED; Saini SD; Chey WD
    Clin Gastroenterol Hepatol; 2019 Dec; 17(13):2687-2695.e11. PubMed ID: 30831219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contrasting Clinician and Insurer Perspectives to Managing Irritable Bowel Syndrome: Multilevel Modeling Analysis.
    Shah ED; Chang L; Salwen-Deremer JK; Gibson PR; Keefer L; Muir JG; Eswaran S; Chey WD
    Am J Gastroenterol; 2021 Apr; 116(4):748-757. PubMed ID: 33982945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of innovation and insurance coverage on price elasticity of demand for prescription drugs: some empirical lessons in pharmacoeconomics.
    Mendoza RL
    J Med Econ; 2020 Sep; 23(9):915-922. PubMed ID: 32432950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing Costs and Outcomes of Treatments for Irritable Bowel Syndrome With Diarrhea: Cost-Benefit Analysis.
    Shah ED; Salwen-Deremer JK; Gibson PR; Muir JG; Eswaran S; Chey WD
    Clin Gastroenterol Hepatol; 2022 Jan; 20(1):136-144.e31. PubMed ID: 33010413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coverage of Novel Therapeutic Agents by Medicare Prescription Drug Plans Following FDA Approval.
    Shaw DL; Dhruva SS; Ross JS
    J Manag Care Spec Pharm; 2018 Dec; 24(12):1230-1238. PubMed ID: 30479199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic, Dietary, and Psychological Treatments for Irritable Bowel Syndrome With Constipation: Cost Utility Analysis.
    Shah ED; Salwen-Deremer JK; Gibson PR; Muir JG; Eswaran S; Chey WD
    MDM Policy Pract; 2021; 6(1):2381468320978417. PubMed ID: 33521290
    [No Abstract]   [Full Text] [Related]  

  • 8. Financial burden of household out-of-pocket expenditures for prescription drugs: cross-sectional analysis based on national survey data.
    McLeod L; Bereza BG; Shim M; Grootendorst P
    Open Med; 2011; 5(1):e1-9. PubMed ID: 22046212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
    Goedken AM; Urmie JM; Farris KB; Doucette WR
    Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
    Kesselheim AS; Avorn J; Sarpatwari A
    JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Why France Spends Less Than the United States on Drugs: A Comparative Study of Drug Pricing and Pricing Regulation.
    Raimond VC; Feldman WB; Rome BN; Kesselheim AS
    Milbank Q; 2021 Mar; 99(1):240-272. PubMed ID: 33751664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How does drug coverage vary by insurance type? Analysis of drug formularies in the United States.
    Régnier SA
    Am J Manag Care; 2014 Apr; 20(4):322-31. PubMed ID: 24884863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prescription drug costs easier to swallow.
    State Legis; 2010 Apr; 36(4):10. PubMed ID: 20397320
    [No Abstract]   [Full Text] [Related]  

  • 14. Economic evaluation of linaclotide for the treatment of adult patients with irritable bowel syndrome with constipation in the United States.
    Huang H; Taylor DC; Carson RT; Sarocco P; Friedman M; Munsell M; Blum SI; Menzin J
    J Med Econ; 2015 Apr; 18(4):283-94. PubMed ID: 25333331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimated effects of adding universal public coverage of an essential medicines list to existing public drug plans in Canada.
    Morgan SG; Li W; Yau B; Persaud N
    CMAJ; 2017 Feb; 189(8):E295-E302. PubMed ID: 28246223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PDP or MA-PD? Medicare part D enrollment decisions in CMS Region 25.
    Cline RR; Worley MM; Schondelmeyer SW; Schommer JC; Larson TA; Uden DL; Hadsall RS
    Res Social Adm Pharm; 2010 Jun; 6(2):130-42. PubMed ID: 20511112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of Prescription Assistance Programs After the Affordable Health Care Act.
    Khan G; Karabon P; Lerchenfeldt S
    J Manag Care Spec Pharm; 2018 Mar; 24(3):247-251. PubMed ID: 29485949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost Effectiveness of Biomarker Tests for Irritable Bowel Syndrome With Diarrhea: A Framework for Payers.
    Almario CV; Noah BD; Jusufagic A; Lew D; Spiegel BMR
    Clin Gastroenterol Hepatol; 2018 Sep; 16(9):1434-1441.e21. PubMed ID: 29596984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physician and Patient Adjustment to Reference Pricing for Drugs.
    Robinson JC; Whaley C; Brown TT; Dhruva SS
    JAMA Netw Open; 2020 Feb; 3(2):e1920544. PubMed ID: 32022881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Managing heterogeneity in prescription drug coverage policies.
    Teagarden JR
    J Manag Care Spec Pharm; 2014 Jun; 20(6):564-5. PubMed ID: 24856594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.